Leah Sherwood

Articles by Leah Sherwood

Leah SherwoodMyelodysplastic Syndromes | March 24, 2023
The EC approval of luspatercept was based on results from the phase II BEYOND study.
Read More
Leah SherwoodT-Cell Lymphoma | March 24, 2023
The approval of the treatment provides patients with an alternative to a product that has historically been in shortage.
Leah SherwoodMyeloma | March 17, 2023
Molly Stoddart, RN, BSN, is a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory.
Leah SherwoodAggressive B-Cell Lymphoma | March 16, 2023
ADX-2191 is a sterile, noncompounded intravitreal formulation of methotrexate.
Leah SherwoodAggressive B-Cell Lymphoma | March 10, 2023
The FDA is expected to make a final decision on the supplemental BLA for polatuzumab vedotin-piiq in DLBCL in early April.
Leah SherwoodMyelodysplastic Syndromes | March 6, 2023
MDS/AML are among independent predictors of COVID-19 treatment failure.
Leah SherwoodAcute Myeloid Leukemia | March 1, 2023
The FDA has approved an Investigational New Drug application for EP0042, a dual FLT-3 and aurora kinase inhibitor.
Leah SherwoodMyeloma | February 27, 2023
The OPTIMUM/MUKnine clinical trial aimed to reduce the risk of relapse before and after AHSCT in ultrahigh-risk MM.
Leah SherwoodAggressive B-Cell Lymphoma | February 27, 2023
AB-101 is an allogeneic, cryopreserved, ADCC-enhancing natural killer-cell therapy.
Leah SherwoodMyeloma | February 23, 2023
The new FDA decision follows its granting of Breakthrough Therapy Designation to elranatamab in November 2022.
Leah Sherwood | February 21, 2023
The AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome took place from January 23-25, 2023.
Leah SherwoodAcute Myeloid Leukemia | February 20, 2023
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
Leah SherwoodTransplantation & Cellular Therapy | February 17, 2023
The study used natural language processing for computer-assisted review of electronic health records.
Leah SherwoodMyeloma | February 15, 2023
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
Leah SherwoodAcute Lymphoblastic Leukemia | February 15, 2023
Ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy in newly diagnosed Ph+ ALL.
Leah SherwoodAcute Myeloid Leukemia | February 13, 2023
The optical genome mapping platform will have clinical implications for patients with acute myeloid leukemia and MDS.
Leah SherwoodAcute Myeloid Leukemia | February 13, 2023
These results have potential implications for the long-term success of venetoclax therapy.
Leah Sherwood | February 10, 2023
The EHA-EBMT 5th European CAR T-Cell Meeting was held February 9-11 in Rotterdam, Netherlands.
Leah SherwoodAggressive B-Cell Lymphoma | February 10, 2023
The results showed pembrolizumab was well tolerated, with 23.5% of patients achieving a complete response.
Leah SherwoodAcute Myeloid Leukemia | February 8, 2023
The study also found DDX41 germline variants explained approximately 80% of known germline predisposition to MNs in adults.